IRIS Institutional Research Information System - OPENBS Open Archive UniBS

TORTI, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.276
EU - Europa 3.815
AS - Asia 3.228
SA - Sud America 25
OC - Oceania 18
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 9
Totale 17.382
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.235
CN - Cina 1.409
UA - Ucraina 1.403
SG - Singapore 814
DE - Germania 735
HK - Hong Kong 649
IT - Italia 411
FI - Finlandia 350
GB - Regno Unito 240
IE - Irlanda 223
RU - Federazione Russa 218
TR - Turchia 190
IN - India 114
FR - Francia 97
SE - Svezia 33
CA - Canada 29
BE - Belgio 27
AU - Australia 16
IR - Iran 16
BR - Brasile 15
AT - Austria 14
NL - Olanda 14
CZ - Repubblica Ceca 13
EU - Europa 9
MX - Messico 7
LT - Lituania 5
AR - Argentina 4
JP - Giappone 4
MU - Mauritius 4
PL - Polonia 4
EC - Ecuador 3
EG - Egitto 3
ES - Italia 3
HU - Ungheria 3
ID - Indonesia 3
LV - Lettonia 3
PA - Panama 3
PH - Filippine 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CH - Svizzera 2
GR - Grecia 2
JO - Giordania 2
KR - Corea 2
KZ - Kazakistan 2
MD - Moldavia 2
MS - Montserrat 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
CY - Cipro 1
GE - Georgia 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
SA - Arabia Saudita 1
TM - Turkmenistan 1
TN - Tunisia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 17.382
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.410
Fairfield 1.409
Jacksonville 1.031
Houston 868
Ann Arbor 704
Ashburn 672
Hong Kong 647
Cambridge 615
Seattle 603
Wilmington 568
Singapore 517
Chandler 431
Princeton 411
Nanjing 393
Dublin 223
Istanbul 170
Beijing 159
Nanchang 147
Helsinki 143
Moscow 105
New York 105
Des Moines 104
San Diego 96
Hebei 92
Shenyang 89
Changsha 83
Jinan 63
Tianjin 63
Lancaster 62
Jiaxing 58
Shanghai 53
Milan 52
Dearborn 51
Kunming 39
Los Angeles 39
Hangzhou 34
Verona 34
Brussels 27
Brescia 26
Toronto 24
London 20
San Francisco 20
Ningbo 19
Boardman 17
Ardabil 16
Lanzhou 16
Zhengzhou 16
Nuremberg 15
Washington 15
Kocaeli 13
Changchun 12
Norwalk 12
Frankfurt am Main 10
Haikou 10
Orange 10
Taizhou 10
Brno 9
Guangzhou 9
Taiyuan 9
Augusta 8
Melbourne 8
Munich 8
Belo Horizonte 7
Nürnberg 7
Rome 7
Auburn Hills 6
Hanover 6
Leawood 6
Monmouth Junction 6
Pune 6
Falkenstein 5
Lappeenranta 5
Palermo 5
Redwood City 5
Carate Brianza 4
Kilburn 4
Sydney 4
Vienna 4
Amsterdam 3
Bratislava 3
Buenos Aires 3
Chicago 3
Chiswick 3
Fuzhou 3
Ottawa 3
Panama City 3
Pavia 3
Phoenix 3
Prague 3
Redmond 3
Riga 3
San Mateo 3
Spilamberto 3
São Paulo 3
Vicenza 3
Walnut 3
Warsaw 3
Ambrogio 2
Amman 2
Athens 2
Totale 12.852
Salva come PNG Salva come JPEG
Nome #
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. 266
The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. 199
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 164
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 151
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 146
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 145
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 140
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 133
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 130
HIV-associated asymmetric lipodystrophy syndrome 129
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 129
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. 128
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 128
Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons 128
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 128
Key Questions in antiretroviral therapy: Italian Consensus Workshop (2005) 126
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 126
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 126
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. 123
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 119
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 117
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 117
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 116
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool 116
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study 115
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 112
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 112
Virological effectiveness and CD4+ T-cell increase over early andlate courses in HIV infected patients on antiretroviral therapy: focus on HCV andanchor class received 112
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 111
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 111
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 110
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 109
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART 109
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 108
All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration  108
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 107
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 106
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 106
Polymorphic immune restoration syndrome after effective HAART 106
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response 106
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial 106
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 106
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction 105
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 104
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis 104
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 104
Risk factors for myocardial infarction in HIV positive patients 103
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 103
Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. 101
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 101
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. 101
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 101
Towards HCV extinction with modern HCV treatment? “Yes we can!” 100
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study 100
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts 100
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 100
First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). 99
The Impact of Gender and Anchor Drugs on TDF Renal Toxicity 98
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 98
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 98
A king in the CASTLE? Optimum initial HIV protease inhibitor. 97
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 97
Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes 97
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 96
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 96
Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound 95
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. 95
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 95
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. 94
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 94
Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. 93
HIV/HTLV co-infection: frequency and epidemiological characteristics among patients admitted to an Italian hospital 93
Risk of triple-class virological failure in children with HIV: a retrospective cohort study 93
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors 92
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 92
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 92
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch 92
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. 91
Natural history of chronic hepatitis B in co-infected patients. 91
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies 91
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission 91
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions 91
Analisi estensiva di sequenza dei geni della trascrittasi inversa e della proteasi di HIV-1 in una coorte clinica di pazienti HIV positivi NAIVE per la terapia antiretrovirale. 90
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 90
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures 89
The use of ultrasonography, transient elestography, APRI and FIB-4 to measure liver steatosis and fibrosis in HIV-positive patients not co-infected with hepatitis viruses with hypertransaminasemia of unknown origin on HAART 89
HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure 89
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal 88
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. 88
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. 88
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) 88
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study 88
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study. 88
Screening and Management of HIV-2-Infected Individuals in Northern Italy. 87
Increasing clinical virulence in two decades of the Italian HIV epidemic 87
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years 87
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 86
No evidence of benefical effect of GB virus type C infection on the course of HIV infection. 86
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. 86
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals 85
Totale 10.747
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.342
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.342
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.247 0 0 0 0 0 0 0 0 333 546 88 280
2020/20212.767 42 324 59 337 105 348 135 394 421 251 265 86
2021/20221.477 76 275 7 89 5 87 61 98 69 195 141 374
2022/20231.374 225 18 11 83 131 416 0 129 228 15 44 74
2023/20241.164 74 24 67 114 46 172 35 32 372 14 15 199
2024/20251.781 28 10 12 339 440 247 319 101 285 0 0 0
Totale 17.537